EvolveMKD picks up more Merz Pharmaceuticals work with Mederma account

The New York-based agency is now working on communications for every Merz Pharmaceuticals brand.

Mederma TV spot (via YouTube)
Mederma TV spot (via YouTube)

RALEIGH, NC: EvolveMKD has won the Mederma account from Merz Pharmaceuticals, meaning that the New York-based agency is now working on PR for every Merz brand.

The firm will handle communications for scar treatment Mederma. In other work for Merz, EvolveMKD is managing the product launch of cellulite-treatment product Cellfina, the 10-year anniversary of injectable Radiesse, and introducing a product line.

"Merz was one of our first clients," said EvolveMKD CEO Megan Driscoll. "The business we primarily started with was their injectables franchise. We now all have all their brands and we are the only PR agency they use."

Merz held a six-month RFP for the Mederma account and chose EvolveMKD from among five agencies, said Jim Hartman, VP of marketing for aesthetics at Merz. Marina Maher Communications was the incumbent on the Mederma account. Merz also previously worked with Behrman Communications.

"Across all bandwidth, whether it be our injectable platform, devices, or OTC franchise with Mederma, we've now got one person," said Hartman. "They’ve done a great job. Being in the realm we’re in – aesthetics and beauty – there’s nothing like surrounding yourself with smart women as thought partners."

Driscoll is leading the Merz account, which is serviced by five other staffers. The firm began working on the business last month. Driscoll began working with Merz in 2013 during her time at Behrman, before she founded EvolveMKD a year later.

Most of the agency’s work is in the aesthetics, dermatology, and beauty markets, plus work for healthcare and lifestyle clients.

"Mederma is such a household name, and it's in the beauty space, which we love, and is also an OB-GYN product," Driscoll said. "It marries the two worlds we’re passionate about."

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in